安罗替尼对非小细胞肺癌患者肺功能的影响及安全性分析

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect and safety of Amlotinib on lung function in patients with non-small cell lung cancer.Methods A total of 48 patients with non-small cell lung cancer treated in the Jiujiang Third People′s Hospital from December 2018 to December 2019 were selected as the research objects,and divided into the observation group(24 cases)and the control group(24 cases)by random number table method.The control group was treated with Paclitaxel Albumin combined with Cisplatin chemotherapy,and the observation group was treated with Amrotinib on the basis of control group.The therapeutic effect,lung function and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 91.67%,which was higher than that of the control group(75.07%),and the difference was statistically significant(P＜0.05).Before treatment,there were no significant differences in forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)and FEV1/FVC between the two groups(P＞0.05).After treatment,the levels of FVC,FEV1 and FEV1/FVC in the two groups were higher than before,and the levels of FVC,FEV1 and FEV1/FVC in the observation group were higher than those in the control group,with statistical significances(P＜0.05).The total incidence of adverse reactions in the observation group was 9.10%,which was lower than that in the control group(25.00%),and the difference was statistically significant(P＜0.05).Conclusion Anlotinib in the treatment of non-small cell carcinoma can effectively improve the lung function of patients,control tumor progression,and promote the recovery of the disease,with high safety.

Key words： Non-small cell lung cancer Anlotinib Paclitaxel albumin Cisplatin chemotherapy Lung function Security

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHU Jie-sheng
	XU Guan-jun
	SHI Yu
	DING Zhi
	FU Jing-zhong▲

Cite this article:

CHU Jie-sheng,XU Guan-jun,SHI Yu, et al. Effect and safety analysis of Amlotinib on lung function in patients with non-small cell lung cancer[J]. 中国当代医药, 2021, 28(17): 100-102.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I17/100

[1]	刘桂红，刘毅，朱蓓，等.局部晚期非小细胞肺癌同步放化疗联合巩固化疗Meta 分析[J].中华肿瘤防治杂志，2018，25（5）：370-374.
[2]	邵扣凤，刘燕文.不同剂型紫杉醇联合顺铂治疗晚期非小细胞肺癌的效果分析[J].临床肿瘤学杂志，2016，21（10）：897.
[3]	罗详冲，刘晶晶，李高峰.安罗替尼治疗晚期恶性肿瘤的研究进展[J].肿瘤，2019，322（12）：71-76.
[4]	陆舜，虞永峰，徐云华，等.肺癌的临床诊断[J].循证医学，2006，6（6）：380.
[5]	王蔚文.临床疾病诊断与疗效判断标准[M].北京：科学技术文献出版社，2010：14.
[6]	张旭超，刘晓庆，王杰，等.间变性淋巴瘤激酶阳性和ros1阳性非小细胞肺癌诊治指南[J].中华病理学杂志，2018，47（4）：241-247.
[7]	赵宇.简易手持式肺功能检测仪在慢性阻塞性肺疾病筛查中的应用价值[J].医疗装备，2020，33（6）：54-55.
[8]	金倩文.局部晚期非小细胞肺癌治疗现状及趋势[J].疑难病杂志，2019，18（8）：860-864.
[9]	郎然，金建军，张彭辉，等.白蛋白结合型紫杉醇联合顺铂对非小细胞肺癌引起的恶性胸腔积液的疗效[J].广东医学，2018，15（39）：2369-2372.
[10]	朱晓敏，王浩楠，郭春龙.多西他赛联合顺铂方案治疗晚期非小细胞肺癌的临床疗效评价[J].中国现代医生，2019，57（1）：65-67.
[11]	李晓兵，薛玉梅，孟岩，等.合并轻度低白蛋白血症的非小细胞肺癌患者多西他赛联合顺铂化疗后不良反应观察[J].山东医药，2018，11（58）：85-87.
[12]	黄伟，解玉卓，赵涵，等.安罗替尼抗肿瘤疗效的研究进展[J].实用药物与临床，2019，22（9）：990-993.
[13]	谢建立，冯丽娟.安罗替尼对老年晚期肺癌患者肺功能及生存质量的影响[J].承德医学院学报，2019，36（2）：129-131.
[14]	何芳，王红梅，贾保昌，等.白蛋白结合型紫杉醇在局部晚期/晚期头颈部肿瘤治疗中的研究进展及展望[J].中国肿瘤临床，2019，46（20）：1061-1066.
[15]	王俊.安罗替尼治疗恶性肿瘤的临床研究进展[J].中国肿瘤，2019，28（5）：359-366.
[16]	Pascale T，Laurent G，Arnaud B，et al.Durvalumab after chemoradiotherapy in stage Ⅲnon-small cell lung cancer[J].J Thorac Dis，2018，10（9）：1032-1036.
[17]	岳恺.安罗替尼胶囊联合顺铂治疗非小细胞肺癌恶性胸腔积液的价值研究[J].中国合理用药探索，2018，15（11）：90-92.